15 Biggest Mid-Day Losers For Tuesday

  • Ra Pharmaceuticals Inc RARX shares dipped 22 percent to $17.30 after the company issued updates on Phase 2 trial of RA101495.
  • Xenon Pharmaceuticals Inc XENE shares dropped 20.6 percent to $3.02 after the company reported results from Phase II study of TV-45070 in patients with PHN. The study did not meet primary and secondary endpoints.
  • Rewalk Robotics Ltd RWLK shares dropped 18.3 percent to $2.45 after surging 25.00 percent on Monday.
  • Alder Biopharmaceuticals Inc ALDR shares declined 17.7 percent to $15.40 despite PROMISE 1 Phase 3 trial which met primary and secondary endpoints. Several notable parts of data set were concerning, namely statistical significance for 100mg dose, and against placebo.
  • Camtek LTD. CAMT shares dipped 12.3 percent to $5.18 after rising 2.25 percent on Monday.
  • Finjan Holdings, Inc. FNJN dropped 12.2 percent to $3.18. Finjan priced 3.6 million shares at $3.15 per share.
  • Matinas BioPharma Holdings Inc MTNB shares declined 11 percent to $1.78.
  • Presbia PLC LENS shares fell 10.9 percent to $2.41.
  • Digiliti Money Group Inc DGLT shares declined 10.1 percent to $2.97.
  • Shiloh Industries, Inc. SHLO shares slipped 9.7 percent to $12.77.
  • IMPINJ Inc PI shares dropped 9.5 percent to $53.76. Pacific Crest downgraded Impinj from Overweight to Sector Weight.
  • Avis Budget Group Inc. CAR shares fell 8.2 percent to $25.39. Avis announced Monday it has formed a partnership with Alphabet Inc GOOGL’s autonomous car business, Waymo.
  • WhiteHorse Finance Inc WHF slipped 6.6 percent to $13.43. WhiteHorse Finance reported an offering of 2.5 million shares of common stock.
  • ARMOUR Residential REIT, Inc. ARR shares declined 5 percent to $26.11. ARMOUR Residential REIT reported a 4.5 million share common stock offering.
  • Neos Therapeutics Inc NEOS shares declined 4.8 percent to $7.00. Neos Therapeutics reported a $30 million offering of common stock.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!